Wellington Management Group
SLNO

Wellington Management Group’s Soleno Therapeutics SLNO Stock Holding History

Wellington Management Group’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,426,781
Closed -$148M – 2060
2026
Q1 		$148M Buy
4,426,781
+1,103,982
+33% +$43.3M 0.03% 445
2025
Q4 		$154M Buy
3,322,799
+1,010,704
+44% +$55.4M 0.03% 447
2025
Q3 		$156M Buy
2,312,095
+1,691,057
+272% +$125M 0.03% 444
2025
Q2 		$52M Sell
621,038
-72,606
-10% -$5.43M 0.01% 679
2025
Q1 		$49.6M Sell
693,644
-88,621
-11% -$4.32M 0.01% 682
2024
Q4 		$35.2M Buy
782,265
+99,095
+15% +$5.13M 0.01% 811
2024
Q3 		$34.5M Buy
683,170
+290,135
+74% +$13.9M 0.01% 811
2024
Q2 		$16M Buy
393,035
+39,554
+11% +$1.68M ﹤0.01% 1015
2024
Q1 		$15.1M Buy
353,481
+140,875
+66% +$6.37M ﹤0.01% 1011
2023
Q4 		$8.56M Buy
+212,606
New +$6.05M ﹤0.01% 1151

Wellington Management Group's SLNO Position: Q2 2026 in Review

Wellington Management Group sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 4,426,781 shares — an estimated $148M sold.

Wellington Management Group first reported a position in SLNO in Q4 2023 and held it in 10 quarters. The position peaked at $156M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

  • Wellington Management Group reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Wellington Management Group sold 4,426,781 Soleno Therapeutics shares in Q2 2026, an estimated $148M.
  • Wellington Management Group first reported a position in Soleno Therapeutics in Q4 2023 and held it in 10 quarters.
  • Wellington Management Group's Soleno Therapeutics position peaked at $156M in Q3 2025.
  • 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.